Understand the source comparison
Best Peptides for Brain Aging Prevention: Complete Comparison
Understanding which peptide fits which aging mechanism requires side-by-side comparison of targets, bioavailability, and evidence quality. P21 CREB pathway activation → synaptic protein synthesis without BDNF dependence Subcutaneous; crosses BBB efficiently (~
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Understanding which peptide fits which aging mechanism requires side-by-side comparison of targets, bioavailability, and evidence quality.
- P21
- CREB pathway activation → synaptic protein synthesis without BDNF dependence
- Subcutaneous; crosses BBB efficiently (~80% bioavailability in CNS)
- Preclinical only. Strong rodent memory data (UCI 2012), no human RCTs
- No standardized human dosing; relies on HED extrapolation from animal models
- Best choice for BDNF-independent memory consolidation. Mechanism is unique but human data remains limited
- Cerebrolysin
- Direct neurotrophic factor delivery (BDNF-like, NGF-like peptides) → neuroprotection and anti-apoptotic signaling
- Intravenous infusion required; direct CNS delivery bypasses oral degradation
- Phase III RCTs in stroke and dementia (>30 trials, meta-analyses in Cochrane Database)
- Requires clinical administration. Not suitable for home use; high cost ($200–400 per course)
- Gold standard for post-injury neuroprotection with robust human data. Impractical for preventive use
- Dihexa
- HGF/Met receptor amplification → synaptogenesis (new synapse formation)
- Oral; small molecule crosses BBB readily (~60% oral bioavailability)
- Preclinical only. WSU synapse formation data is compelling but no Phase I/II safety trials in humans
- Unknown safety profile in humans; no long-term toxicity data
- Most potent synaptogenic compound identified. Mechanism is transformative but human safety remains unproven
- Thymalin
- T-cell modulation → systemic inflammation reduction (indirect CNS benefit via reduced cytokine load)
- Intramuscular; acts systemically rather than CNS-targeted
- 30+ years Russian clinical use but limited Western peer-reviewed RCTs; observational data only
- Effects are indirect. Targets immune aging rather than brain-specific pathways
- Ideal adjunct for immune-mediated cognitive decline. Addresses root cause (inflammation) but not direct neuroprotection